This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

As a main rule, systemic corticosteroids should be classified in this group. There is, however, one exception: M01BA - Antiinflammatory/ antirheumatic agents in combination with corticosteroids. Anticorticosteroids are also classified in this group, see H02CA.
Corticosteroids for local oral treatment, see A01AC.
Enemas and rectal foams for local treatment of e.g. ulcerative colitis, see A07E. Oral corticosteroids solely indicated for the treatment of intestinal inflammatory diseases are classified in A07E - Intestinal antiinflammatory agents.
Corticosteroids for topical use, see D07.
Combined corticosteroid preparations for local treatment of acne, see D10AA.
Corticosteroids in combination with antiinfectives/antiseptics for local treatment of gynecological infections, see G01B.
Corticosteroids for nasal use, see R01AD.
Corticosteroids for inhalation, see R03BA.
Corticosteroids, eye/ear preparations, see S.

Trilostane used in Cushings syndrome is classified in this group.
Mifeprostone used in Cushings syndrome is classified in G03XB.
Metyrapone used in Cushings syndrome is classified in V04CD.
Pharmaceutical formulations of ketoconazole solely indicated in Cushings syndrome are classified in this group.